Rhythm Pharmaceuticals, Inc. Reports Q1 2023 Net Loss of $52.2 Million
Q1 2023 Revenue for Rhythm Pharmaceuticals, Inc. Surges to $11.5 Million
By USInMinutes
Published - Aug 01, 2023, 02:36 PM ET
Last Updated - Aug 01, 2023, 02:36 PM EDT
Rhythm Pharmaceuticals, Inc.(RYTM) has released its unaudited finan cial statements for the first quarter of 2023, revealing a net loss of $52.2 million. However, the company's revenue during the same period surged to $11.5 million, marking a significant improvement compared to the previous year.
Net Loss of $52.2 Million
During the first quarter of 2023, Rhythm Pharmaceuticals, Inc. faced a net loss of $52.2 million. Despite the loss, the company remains optimistic about its growth prospects, as it continues to focus on research and development in the biopharmaceutical sector.
Revenue Reaches $11.5 Million
